Cargando…

Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors

AIMS: To compare the influence of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) on the risk of lower extremity amputations in patients with type 2 diabetes in Slovenia. METHODS: This retrospective cohort study included patients aged 40 years or mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zerovnik, Spela, Kos, Mitja, Locatelli, Igor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841312/ https://www.ncbi.nlm.nih.gov/pubmed/34609620 http://dx.doi.org/10.1007/s00592-021-01805-8

Ejemplares similares

Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
por: Zerovnik, Spela, et al.
Publicado: (2021)

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study
por: Yuan, Zhong, et al.
Publicado: (2017)

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
por: Heyward, James, et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Prevalence and Incidence of Frailty Among Community-dwelling Older Adults in Slovenia
por: Jazbar, Janja, et al.
Publicado: (2021)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Type 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions
por: Nerat, Tomaž, et al.
Publicado: (2016)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study
por: Werkman, Nikki C. C., et al.
Publicado: (2023)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
por: Iwamoto, Masahiko, et al.
Publicado: (2022)

On Amputation in Cases of Gangrene of the Lower Extremity
por: Caird, Francis M.
Publicado: (1893)

On Amputation in Cases of Gangrene of the Lower Extremity
por: Caird, Francis M.
Publicado: (1893)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers
por: Ali, Kabeer, et al.
Publicado: (2021)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
por: Chan, Anthony T. P., et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
por: Hropot, Tim, et al.
Publicado: (2023)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
por: Torimoto, Keiichi, et al.
Publicado: (2017)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
por: Kushner, Pamela
Publicado: (2016)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qbulh8g1nbn9c117m88lf0sjn5